Leena Das-Young is the Head of Late Phase Stage Strategy and Development Group, Oncology Global Product Development at Pfizer. She is an accomplished senior pharmaceutical executive leading large organizations/teams to develop, commercialize and expand blockbuster products. Her experience spans diverse functional areas across the development continuum including leadership of geographically distributed teams, product development and commercial leadership. She has demonstrated success in driving cutting-edge scientific leadership, business strategy, and revenue growth. In her current role, she serves as the head of the late phase oncology portfolio, asset team leaders, project and submissions management organizations. Assets include, Ibrance, Xalkori, Sutent and others. Her teams are responsible for products starting at proof-of-concept through submission, registration, lifecycle management through to loss of exclusivity. Prior to her current asset group role, Leena served as the Asset Team Leader for XALKORI and for SUTENT. As a commercial leader, Leena led the marketing for blockbuster agents including SUTENT, Camptosar, and Cipro. Prior to joining industry, Leena served as a clinical pharmacist leading institutional P & T committees in tertiary care centers as well as the research efforts in a large AIDs clinic. Leena holds a B.S. in Pharmacy and a Doctor of Pharmacy (Pharm.D.) from Purdue University.